跳至主要内容
临床试验/NCT02248792
NCT02248792Unknown4 期

Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study.

Narayana Medical College & Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2013年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
50
试验地点
1
主要终点
Improvement in health related quality of life

研究概览

简要总结

Methotrexate (MTX) is considered the 'gold-standard' drug for the treatment of severe psoriasis. Health-related quality of life (HRQOL) is impaired in patients with psoriasis, more so if disease is severe.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age range 18 to 65 years Both sexes Severe plaque-type psoriasis (BSA >10% or PASI >12) -

排除标准

  • Pregnancy Lactation Malignancy or immunosuppression including HIV Liver disease Renal disease Non compliant Psychiatric illness Hypersensitivity to methotrexate in the past

研究组 & 干预措施

Group A

Experimental

Methotrexate 10mg orally once weekly

干预措施: Methotrexate (Drug)

Group B

Active Comparator

Methotrexate 25mg orally once weekly

干预措施: Methotrexate (Drug)

结局指标

主要结局

Improvement in health related quality of life

时间窗: 12 weeks

次要结局

  • comparison of improvement in health related quality of life between Group A and Group B(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

C V Krishna

C V Krishna

Narayana Medical College & Hospital

研究点 (1)

Loading locations...

相似试验

Quality of Life of Patients With Psoriasis Treated... | 临床试验